Back

Ataxin-2

Official Title

A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene

Study Details

The purpose of the study is to examine the safety and tolerability of a study drug in participants with sporadic ALS (amyotrophic lateral sclerosis).

Principal Investigator

Dr. Robert Bucelli

IRB Number

202007038

Eligibility

1. Participants must be 18 or older
2. Participants must have ALS
3. Participants must have a caregiver available for the duration of the research study



Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back